AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.91 |
Market Cap | 40.09M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.53 |
PE Ratio (ttm) | -0.6 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.92 |
Volume | 809,940 |
Avg. Volume (20D) | 3,136,634 |
Open | 0.94 |
Previous Close | 0.92 |
Day's Range | 0.90 - 0.94 |
52-Week Range | 0.70 - 6.00 |
Beta | undefined |
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...
Analyst Forecast
According to 4 analyst ratings, the average rating for TPST stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 1315.35% from the latest price.